Drug intelligence / Profile preview

enalapril + spironolactone + carvedilol

Development stage
Phase 4
Lead developer
Roche
Modality
Small Molecules
Administration
Oral
01

Overview

enalapril + spironolactone + carvedilol is a combination pharmacological regimen investigated for the treatment of chronic Chagas cardiomyopathy. The regimen consists of two renin-angiotensin system (RAS) inhibitors—enalapril (an ACE inhibitor) and spironolactone (a mineralocorticoid receptor antagonist)—and carvedilol, a non-selective beta-blocker with alpha-1 blocking activity. This therapeutic strategy, studied by the Federal University of Minas Gerais in the NCT01557140 trial, aims to mitigate the progressive cardiac damage and neurohormonal activation characteristic of Trypanosoma cruzi infection. Clinical findings suggest the combination is safe and effective in improving left ventricular ejection fraction and clinical status in patients with Chagas-related heart failure.

Other names
RASi + carvedilolRAS inhibitors + carvedilol
02

Targets

ADRA1A (α1A)ACE (Angiotensin Converting Enzyme)ADRB1 (β1)ADRB2 (β2)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)

Beyond the preview

Go deeper on enalapril + spironolactone + carvedilol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enalapril + spironolactone + carvedilol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call